OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Researchers at Oregon State University (OSU) are reporting that they have come up with a new nanotech drug delivery system that may combat melanoma in a whole new way.

A 32-year-old woman presents with a cutaneous nodule and a biopsy is performed. What is your diagnosis?

Gut bacteria improve antitumor immunity and the efficacy of antitumor immune checkpoint-blockade therapy, according to a pair of recently published studies..

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.

Genetic mutation analysis confirms the malignant potential of intermediate skin lesions that are neither benign moles nor yet melanomas.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.